Klaus Wagner
Chief Tech/Sci/R&D Officer at BOUNDLESS BIO, INC.
Net worth: - $ as of 2024-05-30
Profile
Klaus W.
Wagner is currently the Chief Medical Officer at Boundless Bio, Inc. Prior to his current position, he served as the Chief Medical Officer & Executive Vice President at Inhibrx, Inc. from 2015 to 2022.
Dr. Wagner holds a doctorate degree from Friedrich-Alexander University of Erlangen-Nuremberg.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BOUNDLESS BIO INC.
-.--% | 2024-03-27 | 0 ( -.--% ) | - $ | 2024-05-30 |
Klaus Wagner active positions
| Companies | Position | Start |
|---|---|---|
| BOUNDLESS BIO, INC. | Chief Tech/Sci/R&D Officer | 2022-02-19 |
Former positions of Klaus Wagner
| Companies | Position | End |
|---|---|---|
| INHIBRX, INC. | Chief Tech/Sci/R&D Officer | 2022-01-31 |
Training of Klaus Wagner
| Friedrich-Alexander University of Erlangen-Nuremberg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BOUNDLESS BIO, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Inhibrx, Inc.
 Inhibrx, Inc. BiotechnologyHealth Technology Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA. | Health Technology |
- Stock Market
- Insiders
- Klaus Wagner
